{"id":"tp-40303","type":"article-newspaper","title":"Zymeworks Presents Phase 1 ZW191 Activity in Resistant Ovarian Cancer","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/40303","datePublished":"2026-10-24T20:18:17.000Z","dateModified":"2026-10-24T20:18:17.000Z","language":"en","abstract":"The heavily pretreated study population had platinum-resistant disease. The response-rate analysis focused on high-grade serous ovarian cancer.","section":"Business","references":[]}